Kathryn Anne Defea
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2021First federal award
$2.6MFederal grants as PI5 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
5 awards · $2.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Mar 25, 2025 | NIH | SBIR Phase II Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma | $793K | PARMEDICS, INC |
| Mar 6, 2024 | NIH | SBIR Phase II Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma | $878K | PARMEDICS, INC |
| Sep 14, 2023 | NIH | STTR Phase I Development of small molecule Protease-activated-receptor-2 antagonists as oral asthma therapeutics | $300K | PARMEDICS, INC |
| Jan 13, 2023 | NIH | STTR Phase I Protease-activated-receptor-2 antagonists for treatment of migraine pain | $310K | PARMEDICS, INC |
| Sep 1, 2021 | NIH | STTR Phase I Development of Small Molecule Antagonists of PAR-2 for treatment of asthma | $283K | PARMEDICS, INC |
Peer ranks
Federal funding#742
Awards as PI#417
Patents#273
Companies
- PARMEDICS, INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.